Daclizumab (Zenapax®) inhibits early interleukin-2 receptor signal transduction events
- 1 November 2000
- journal article
- Published by Elsevier in Transplant Immunology
- Vol. 8 (3) , 153-159
- https://doi.org/10.1016/s0966-3274(00)00021-6
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- DIVERGENT ROLES FOR FcRECEPTORS AND COMPLEMENT IN VIVOAnnual Review of Immunology, 1998
- A PHASE I TRIAL OF HUMANIZED ANTI-INTERLEUKIN 2 RECEPTOR ANTIBODY IN RENAL TRANSPLANTATION1Transplantation, 1997
- The Interleukin-2 Receptor γ Chain: Its Role in the Multiple Cytokine Receptor Complexes and T Cell Development in XSCIDAnnual Review of Immunology, 1996
- PROLONGED ACTION OF A CHIMERIC INTERLEUKIN-2 RECEPTOR (CD25) MONOCLONAL ANTIBODY USED IN CADAVERIC RENAL TRANSPLANTATIONTransplantation, 1995
- Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor alpha, beta, and gamma chains.The Journal of cell biology, 1995
- Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12.The Journal of Experimental Medicine, 1995
- Cytoplasmic domains of the interleukin-2 receptor β and γ chains mediate the signal for T-cell proliferationNature, 1994
- Heterodimerization of the IL-2 receptor β- and γ-chain cytoplasmic domains is required for signallingNature, 1994
- The IL-2 Receptor Complex: Its Structure, Function, and Target GenesAnnual Review of Immunology, 1993
- lnterleukin-2 programs mouse αβ T lymphocytes for apoptosisNature, 1991